Description

STAD 2 is a potent and selective disruptor of PKA-RII, with a Kd of 6.2 nM. STAD 2 disrupts interactions between PKA and AKAP in an isoform-selective manner. STAD 2 displays antimalarial activity through a PKA-independent mechanism[1][2].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)—-C102H182N24O22—-[1]Wang Y, et, al. Isoform-selective disruption of AKAP-localized PKA using hydrocarbon stapled peptides. ACS Chem Biol. 2014 Mar 21;9(3):635-42.|[2]Flaherty BR, et, al. The Stapled AKAP Disruptor Peptide STAD-2 Displays Antimalarial Activity through a PKA-Independent Mechanism. PLoS One. 2015 May 26;10(5):e0129239.–1542100-77-5–2096.68–98.39–CC(C)C[C@H](NC([C@H](C)NC([C@]1(C)CCC/C=C/CCC[C@](C(N[C@@H](C)C(N[C@@H](CC(C)C)C(N[C@@H](CCCCN)C(N1)=O)=O)=O)=O)(C)NC([C@H](CO)NC([C@@H](NC([C@H](CC(C)C)NC([C@H](CC2=CC=CC=C2)NC([C@H](CCCCN)NC([C@H](C)NC([C@H](CC(C)C)NC([C@H](CCCCN)NC([C@H](CCCCN)NC(COCCOCCOCCN)=O)=O)=O)=O)=O)=O)=O)=O)C(C)C)=O)=O)=O)=O)C(N[C@@H](CCCCN)C(N)=O)=O–Infection–DMSO : ≥ 100 mg/mL–PKA—-Stem Cell/Wnt;TGF-beta/Smad–Peptides